Format

Send to

Choose Destination
Clin Cancer Res. 2018 Feb 15;24(4):870-881. doi: 10.1158/1078-0432.CCR-17-2337. Epub 2017 Dec 7.

T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Author information

1
Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
2
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
3
Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.
4
Department of Pathology, Oslo University Hospital, Oslo, Norway.
5
Immunology Laboratory, Ospedale Policlinico San Martino, Genova, Italy.
6
Department of Computer Science, University of Oslo, Oslo, Norway.
7
Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway.
8
Division of Oncology, Stanford School of Medicine, Stanford, California.
9
Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee.
10
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
11
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
12
Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway. junehm@rr-research.no.

Abstract

Purpose: T cells infiltrating follicular lymphoma (FL) tumors are considered dysfunctional, yet the optimal target for immune checkpoint blockade is unknown. Characterizing coinhibitory receptor expression patterns and signaling responses in FL T-cell subsets might reveal new therapeutic targets.Experimental Design: Surface expression of 9 coinhibitory receptors governing T-cell function was characterized in T-cell subsets from FL lymph node tumors and from healthy donor tonsils and peripheral blood samples, using high-dimensional flow cytometry. The results were integrated with T-cell receptor (TCR)-induced signaling and cytokine production. Expression of T-cell immunoglobulin and ITIM domain (TIGIT) ligands was detected by immunohistochemistry.Results: TIGIT was a frequently expressed coinhibitory receptor in FL, expressed by the majority of CD8 T effector memory cells, which commonly coexpressed exhaustion markers such as PD-1 and CD244. CD8 FL T cells demonstrated highly reduced TCR-induced phosphorylation (p) of ERK and reduced production of IFNγ, while TCR proximal signaling (p-CD3ζ, p-SLP76) was not affected. The TIGIT ligands CD112 and CD155 were expressed by follicular dendritic cells in the tumor microenvironment. Dysfunctional TCR signaling correlated with TIGIT expression in FL CD8 T cells and could be fully restored upon in vitro culture. The costimulatory receptor CD226 was downregulated in TIGIT+ compared with TIGIT- CD8 FL T cells, further skewing the balance toward immunosuppression.Conclusions: TIGIT blockade is a relevant strategy for improved immunotherapy in FL. A deeper understanding of the interplay between coinhibitory receptors and key T-cell signaling events can further assist in engineering immunotherapeutic regimens to improve clinical outcomes of cancer patients. Clin Cancer Res; 24(4); 870-81. ©2017 AACR.

PMID:
29217528
PMCID:
PMC5815910
[Available on 2019-02-15]
DOI:
10.1158/1078-0432.CCR-17-2337

Supplemental Content

Full text links

Icon for HighWire Icon for Norwegian BIBSYS system
Loading ...
Support Center